Valley National Advisers’s abrdn Life Sciences Investors HQL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
Sell
-644
Closed -$10K 805
2020
Q1
$10K Hold
644
﹤0.01% 466
2019
Q4
$11K Hold
644
﹤0.01% 512
2019
Q3
$10K Hold
644
﹤0.01% 504
2019
Q2
$11K Hold
644
﹤0.01% 463
2019
Q1
$11K Sell
644
-665
-51% -$11.5K ﹤0.01% 471
2018
Q4
$20K Sell
1,309
-1,492
-53% -$26.3K 0.01% 363
2018
Q3
$57K Sell
2,801
-228
-8% -$4.54K 0.02% 249
2018
Q2
$57K Hold
3,029
0.02% 251
2018
Q1
$58K Hold
3,029
0.02% 238
2017
Q4
$59K Hold
3,029
0.02% 234
2017
Q3
$65K Hold
3,029
0.02% 231
2017
Q2
$63K Sell
3,029
-20
-0.7% -$404 0.02% 228
2017
Q1
$59K Sell
3,049
-106
-3% -$1.96K 0.02% 230
2016
Q4
$54K Hold
3,155
0.02% 245
2016
Q3
$59K Sell
3,155
-90
-3% -$1.7K 0.03% 216
2016
Q2
$56K Hold
3,245
0.03% 220
2016
Q1
$58K Hold
3,245
0.03% 221
2015
Q4
$77K Hold
3,245
0.05% 194
2015
Q3
$73K Buy
3,245
+15
+0.5% +$420 0.04% 204
2015
Q2
$91K Sell
3,230
-59
-2% -$1.64K 0.05% 195
2015
Q1
$91K Buy
3,289
+886
+37% +$24.2K 0.05% 179
2014
Q4
$49K Buy
+2,403
New +$57.7K 0.04% 164

Other funds holding HQL

Valley National Advisers's HQL Position: Q2 2020 in Review

Valley National Advisers sold out of abrdn Life Sciences Investors (HQL) in Q2 2020, closing a stake of 644 shares — an estimated $10K sold.

Valley National Advisers first reported a position in HQL in Q4 2014 and held it in 22 quarters. The position peaked at $91K in Q2 2015. 70 funds tracked by Wall St. Rank hold HQL as of Q2 2020.

  • Valley National Advisers reported no remaining abrdn Life Sciences Investors position as of Q2 2020 after selling out during the quarter.
  • Valley National Advisers sold 644 abrdn Life Sciences Investors shares in Q2 2020, an estimated $10K.
  • Valley National Advisers first reported a position in abrdn Life Sciences Investors in Q4 2014 and held it in 22 quarters.
  • Valley National Advisers's abrdn Life Sciences Investors position peaked at $91K in Q2 2015.
  • 70 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2020.

Based on Valley National Advisers's 13F filing for Q2 2020, filed 10 Aug 2020.